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Metabolic  syndrome  is  associated  with  better
nutritional  status,  but  not  with  cardiovascular
disease  or  all-cause  mortality  in  patients  on
haemodialysis
Le  syndrome  métabolique  est  associé  à  un  meilleur  statut  nutritionnel,  mais
non  avec  la  maladie  cardiovasculaire  ou  la  mortalité  toute  cause  chez  les
patients  hémodialysés
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Summary
Background.  —  Metabolic  syndrome  increases  the  risk  of  cardiovascular  disease  (CVD)  and  all-
cause mortality  in  the  general  population.
Aims.  —  To  investigate  whether  metabolic  syndrome  affects  CVD  and  all-cause  mortality  in
chronic haemodialysis  patients.
Methods.  —  This  prospective,  observational  cohort  study  was  carried  out  at  Peking  universitydisease third hospital  from  June  2006  to  June  2010.  Baseline  anthropometric  and  laboratory  parameters
were evaluated,  and  causes  and  times  of  mortality  were  documented.  Nutritional  status  of  the
patients was  assessed  using  subject  global  assessment  (SGA)  and  serum  albumin  levels.
Results.  —  Of  162  haemodialysis  patients  recruited,  ﬁve  were  lost  to  follow-up,  leaving  157
in the  ﬁnal  cohort,  who  were  followed  for  36−42  months.  Mean  age  was  62  ±  11  years  and
Abbreviations: BMI, Body Mass Index; CVD, Cardiovascular Disease; DBP, Diastolic Blood Pressure; FPG, Fasting Plasma Glucose; HDL-C,
High-Density Lipoprotein Cholesterol; IDF, International Diabetes Federation; MS, Metabolic Syndrome; NCEP/ATPIII, National Cholesterol
Education Program/Adult Treatment Panel III; PTH, Parathyroid Hormone; SBP, Systolic Blood Pressure; SD, Standard Deviation; SGA,
Subject Global Assessment; hs-CRP, High-Sensitivity C-Reactive Protein.
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55.4%  were  men.  Forty-six  patients  (30%)  had  metabolic  syndrome.  In  the  metabolic  syndrome
versus the  non-metabolic  syndrome  group,  there  were  fewer  patients  with  malnutrition  (by
SGA) (15.2%  vs.  55.0%;  P  <  0.001),  but  there  were  no  signiﬁcant  differences  in  CVD  mortality
(8.7% vs.  10.8%;  P  =  0.9)  or  all-cause  mortality  (15.2%  vs.  22.5%;  P  =  0.39),  nor  in  mean  observed
survival  time  (30.8  ±  7.3  vs.  29.8  ±  8.5  months;  P  =  0.49)  or  total  survival  time  (67  ±  43  vs.  78
± 48  months;  P  =  0.20).  Cox  regression  analysis  showed  that  independent  mortality  risk  factors
were pre-existing  CVD,  age  more  than  or  equal  to  66  years  and  serum  albumin  less  than  37  g/L
(indicating  malnutrition).
Conclusion.  —  Metabolic  syndrome  was  associated  with  a  better  nutritional  status,  but  not  with
CVD or  all-cause  mortality  in  the  haemodialysis  patients  in  this  prospective  cohort  study.
© 2012  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé
Justiﬁcation.  — Le  syndrome  métabolique  augmente  le  risque  d’affection  cardiovasculaire  et
de mortalité  toute  cause  dans  la  population  générale.
Objectifs.  —  Évaluer  l’hypothèse  que  le  syndrome  métabolique  pourrait  retentir  sur  le  risque
cardiovasculaire  de  la  mortalité  globale  chez  des  patients  en  hémodialyse  chronique.
Méthode.  —  Cette  étude  prospective,  observationnelle  de  cohortes  a  été  effectuée  dans
l’université  de  Pékin  entre  juin  2006  et  juin  2010.  Les  caractéristiques  anthropométriques  et
biologiques  ont  été  évaluées  ainsi  que  les  causes  et  les  modalités  de  survenue  d’évènements
dont la  mortalité.  Le  statut  nutritionnel  des  patients  était  évalué  en  utilisant  l’échelle  SGA
ainsi que  les  concentrations  sériques  d’albumine.
Résultats.  —  Parmi  les  162  patients  hémodialysés  chroniques  inclus,  cinq  ont  été  perdus  de  vue,
permettant  d’analyser  au  sein  de  la  cohorte  157  patients,  suivis  de  36  à  42  mois.  L’âge  moyen
était de  62  ±  11  ans  et  55,4  %  étaient  des  patients  de  sexe  masculin.  Quarante-six  patients
(30 %)  présentaient  un  syndrome  métabolique.  En  comparant  les  groupes  avec  et  sans  syndrome
métabolique,  il  y  avait  un  nombre  moindre  de  patients  souffrant  de  malnutrition  évalués  par
SGA (15,2  %  vs  55  %,  p  <  0,001),  mais  il  n’y  avait  pas  de  différence  signiﬁcative  en  ce  qui  concerne
la mortalité  cardiovasculaire  (8,7  %  vs  10,8  %,  p  =  0,9)  ou  de  mortalité  totale  (15,2  %  vs  22,5  %,
p =  0,39).  Il  n’y  avait  pas  non  plus  de  différence  signiﬁcative  en  ce  qui  concerne  le  délai  de
survenue  (30,8  ±  7,3  vs  29,8  ±  8,5  mois,  p  =  0,49)  ou  la  durée  totale  de  survie  au  cours  du
suivi (67  ±  43  vs  78  ±  48  mois,  p  =  0,20)  au  sein  de  cette  cohorte.  L’analyse  par  régression  de
Cox a  montré  que  les  facteurs  de  risque  indépendants  de  mortalité  étaient  la  présence  d’une
pathologie  cardiovasculaire  préexistante,  un  âge  supérieur  ou  égal  à  66  ans  et  un  taux  sérique
d’albumine  inférieur  à  37  g/L,  synonyme  de  malnutrition.
Conclusion.  — Le  syndrome  métabolique  est  associé  à  un  meilleur  statut  nutritionnel,  mais
pas avec  un  excès  d’évènements  cardiovasculaires  ou  de  mortalité  totale  chez  les  patients
hémodialysés,  suivis  au  sein  d’une  cohorte  prospective.
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S,  which  refers  to  a  group  of  metabolic  risk  factors,  has
een  found  in  recent  meta-analyses  to  increase  the  risk  of
ncident  CVD  and  all-cause  mortality  in  the  general  popu-
ation  [1—3]. Current  literature  most  frequently  cites  the
eﬁnitions  of  MS  provided  by  the  NCEP/ATP  III  [4]  and  the
DF  (2005)  [5].
CVD  is  the  most  common  cause  of  hospitalization  and
eath  in  chronic  haemodialysis  patients  [6].  However,
ome  risk  factors  for  CVD  in  the  general  population  (e.g.
yperlipidaemia,  hypertension  and  obesity)  have  been
ssociated  with  a  relatively  good  prognosis  among  dialysis
atients  [7—12]. This  phenomenon  is  known  as  reverse
pidemiology  [13]. We  therefore  hypothesized  that  MS
ay  not  have  a  negative  effect  on  mortality;  particularly
ortality  associated  with  CVD,  in  haemodialysis  patients.
c
cs  droits  réservés.
ethods
atients
atients  were  recruited  from  the  haemodialysis  centre
t  Peking  university  third  hospital  from  June  2006  to
ecember  2007.  Patients  had  to  have  received  haemodial-
sis  for  more  than  or  equal  to  3  months;  patients
ho  started  dialysis  less  than  3  months  previously  and
rregular  dialysis  patients  were  not  eligible  for  inclu-
ion.  All  eligible  regular  dialysis  patients  in  the  centre
ere  included,  unless  they  did  not  agree  to  participate
n  the  study.  Dialysis  lasts  4—5  hours  at  each  session
nd  is  conducted  three  times  each  week.  The  ethics
ommittee  of  Peking  university  approved  the  study  proto-
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Follow-up and endpoints
Patients  were  classiﬁed  based  on  the  presence  or  absence
of  MS,  and  were  prospectively  followed  until  June  2010  or
until  death,  if  this  event  occurred  earlier.  The  dates  of  death
were  deﬁned  as  endpoints.
Deﬁnitions
The  2006  IDF  deﬁnition  of  MS  was  used:  central  obesity
(waist  circumference  more  than  or  equal  to  80  cm  in  Asian
women  or  more  than  or  equal  to  90  cm  in  Asian  men)  plus
two  of  the  following  factors:
•  elevated  triglycerides  (more  than  or  equal  to  1.69
mmol/L)  or  speciﬁc  treatment  for  this  lipid  abnormality;
•  reduced  HCL-C  (less  than  1.03  mmol/L  in  men  or  less  than
1.29  mmol/L  in  women)  or  speciﬁc  treatment  for  this  lipid
abnormality;
•  elevated  blood  pressure  (SBP  more  than  or  equal  to
130  mmHg  or  DBP  more  than  or  equal  to  85  mmHg)  or
treatment  for  previously  diagnosed  hypertension;
•  elevated  fasting  plasma  glucose  (more  than  or  equal  to
5.55  mmol/L)  or  a  previous  diagnosis  of  type  2  diabetes.
CVD  was  deﬁned  as  coronary  artery  disease,  arrhythmia,
heart  failure,  peripheral  vascular  disease  or  cerebrovascular
disease.
Laboratory and anthropometric variables
Biochemical  data  were  collected  at  baseline  and  included
haemoglobin,  serum  creatinine,  serum  triglycerides,  HDL-C,
FPG,  serum  albumin,  hs-CRP  and  serum  intact  PTH  lev-
els.  All  tests  were  performed  in  the  central  laboratory  of
our  hospital  using  standard  methods.  Blood  pressure  (taken
with  the  patient  in  the  sitting  position),  height,  weight  and
waist  circumference  (at  umbilical  level  in  a  standing  posi-
tion)  were  recorded.  Each  patient’s  nutritional  status  was
assessed  by  SGA  methods  (A  =  normal  nutrition,  B  =  mild  mal-
nutrition,  C  =  severe  malnutrition)  according  to  the  patient’s
weight,  food  intake,  symptoms  (nausea,  vomiting,  diarrhoea
and  constipation),  activities  and  function,  disease  and  its
relation  to  nutritional  requirement,  metabolic  demand  and
physical  ﬁndings  [14].
Body composition measurement
Post-dialysis  body  composition  was  analysed  by  Bioelectrical
Impedance  (BIA,  Tanita,  Japan).  The  collected  data  included
body  fat  (%  and  kg),  lean  body  mass  (kg),  muscle  mass  (kg)
and  visceral  fat  rating  (1—59  grade;  where  1—12  is  consid-
ered  healthy  while  more  than  or  equal  to  13  corresponds  to
excessive  abdominal  fat  and  indicates  central  obesity).  The
measurements  were  performed  by  skilled  staff  who  were
experienced  at  collecting  these  measurements.
Statistical analysisContinuous  variables  are  expressed  as  the  mean  ±  SD,  while
frequency  variables  are  expressed  as  count  (%).  Contin-
uous  variables  were  compared  using  one-way  analysis  of
variance  or  non-parameter  testing  between  the  two  groups
w
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lassiﬁed  by  the  presence  or  absence  of  MS.  Frequency  varia-
les  were  compared  using  the  2 test.  A  Cox  regression
odel  was  performed  to  determine  risk  factors  for  mortal-
ty.  The  assumption  of  proportionality  was  assessed  through
he  analysis  of  partial  residuals  of  the  covariates  introduced
nto  the  models.  Survival  between  patients  with  and  without
S  was  compared  using  Kaplan-Meier  analysis  and  a  log-rank
est.  A  P-value  <  0.05  was  considered  statistically  signiﬁcant.
ll  statistical  calculations  were  performed  using  SPSS  13.0
or  Windows.
esults
aseline characteristics
 total  of  162  patients  were  recruited;  ﬁve  were  transferred
o  other  haemodialysis  centres,  leaving  157  in  the  ﬁnal
ohort,  of  whom  99  underwent  post-dialysis  body  compo-
ition  analysis.  Of  the  157  patients  included,  46  patients
30%)  had  MS  by  the  IDF  criteria  [5].  All  patients  were  of
hinese  origin.  Other  baseline  characteristics  are  shown  in
able  1.  The  dialysis  vintage  at  baseline  was  signiﬁcantly
horter  among  diabetic  versus  other  haemodialysis  patients
24  ±  23  vs.  50  ±  49  months,  Z  =  —2.884;  P  =  0.004).
Not  surprisingly,  patients  with  MS  had  signiﬁcantly  higher
MI,  body  fat,  visceral  fat  rating  and  waist  circumference
Table  1).  They  also  had  signiﬁcantly  higher  concentrations
f  haemoglobin,  serum  albumin  and  triglycerides;  but  signi-
cantly  lower  HDL-C  (Table  1).  More  MS  patients  had  normal
utrition  (A,  assessed  by  SGA)  than  those  without  MS  (84.8%
s.  45.0%;  P  <  0.001;  Table  1).  There  were  no  signiﬁcant  dif-
erences  in  sex  or  prevalence  of  pre-existing  CVD  between
he  two  groups  (Table  1).
ssociation between all-cause mortality and
etabolic syndrome
ll  patients  were  followed  for  36—42  months.  During  this
ime,  seven  patients  with  MS  and  25  patients  without  MS
ied  (15.2%  vs.  22.5%;  P  =  0.39),  most  commonly  of  CVD
Table  2).  There  were  no  signiﬁcant  differences  in  observed
r  total  survival  times  between  the  two  groups  (Table  2;
ig.  1),  although  total  survival  was  somewhat  shorter  among
atients  with  MS  (67  vs.  78  months;  P  = 0.20;  Table  2).  Total
urvival  time  was  signiﬁcantly  shorter  among  patients  with
ersus  without  diabetes  (54  ±  23  vs.  80  ±  50  months;  Z  =
2.582;  P  =  0.01).
omparison of baseline characteristics by
urvival
o  further  analyse  the  risk  factors  for  death,  the  157  patients
ere  reclassiﬁed  according  to  survival  and  death  and  the
aseline  clinical  characteristics  compared  between  these
wo  groups  (Table  3).  Compared  with  surviving  patients,
atients  who  died  were  older  and  had  lower  muscle  mass
nd  serum  albumin  levels  (Table  3).  Additionally,  there
ere  more  patients  with  malnutrition  (B,  assessed  by
GA)  and  pre-existing  CVD  in  the  all-cause  mortality  group
Table  3).  However,  there  were  no  signiﬁcant  differences  in
BP,  BMI,  waist  circumference  or  percentage  with  diabetic
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Table  1  Baseline  characteristics.
All  patients  (n  =  157)  MS  (n  =  46)  Non-MS  (n  =  111)  P
Age  (years) 62 ±  11  63  ±  10  61  ±  13  0.45
Men  87  (55.4)  22  (47.8)  65  (58.6)  0.36a
Primary  renal  disease
Glomerulonephritis 51  (32.5)  13  (28.2)  38  (34.2)  0.21a
Hypertensive  glomerulosclerosis 40  (25.5) 12  (26.0)  28  (24.8)  0.30a
Diabetes 30  (19.1) 12  (26.8) 18  (16.0) 0.30a
Other 36  (22.9) 9  (19.0) 27  (25.0) 0.29a
Dialysis  vintage  (months)  44  ±  46  36  ±  43  47  ±  47  0.18
Predialysis  SBP  (mmHg)  141  ±  12  144  ±  19  141  ±  29  0.45
BMI  (kg/m2)  24.0  ±  3.7  26.2  ±  3.7  22.5  ±  3.2  <  0.001
Body  fat  (%)b 27.8  ±10.2  33.1  ±  9.3  25.0  ±  9.3  <  0.001
Body  fat  (kg)b 18.0  ±  8.3  23.4  ±  8.2  15.3  ±  6.7  <  0.001
Lean  body  mass  (kg)b 46.2  ±  8.4  46.8  ±  9.4  45.7  ±  7.7  0.55
Muscle  mass  (kg)b 43.7  ±  8.0  44.3  ±9.1  43.4  ±7.9  0.90
Visceral  fat  rating  (grade)b 11.1  ±  4.3  13.5  ±  4.6  9.7  ±  3.6  <  0.001
Waist  circumference  (cm) 86 ±  8 90  ±  8  83  ±  6  <  0.001
Malnutrition  (B,  assessed  by  SGA) 48 (43.3)  7  (15.2)  61  (55.0)  <  0.001a
Haemoglobin  (g/L) 111 ±  15 116 ±  10  109  ±  16  0.02
Serum  albumin  (g/L) 40.0  ±  2.9 41.0  ±  1.8 40.0  ±  3.1  0.01
Triglycerides  (mmol/L) 2.1 ±  1.4 2.8 ±  1.5  1.8  ±  1.2  0.001
HDL-C  (mmol/L) 1.3 ±  0.5 1.1 ±  0.4 1.3  ±  0.6  0.013
Total  cholesterol  (mmol/L) 4.2  ±  0.8 4.6 ±  0.7 4.1  ±  0.7 < 0.001
Fasting  glucose  (mmol/L) 5.4  ±  0.3 6.1 ±  0.4 5.1  ±  0.3  0.017
PTH  (pg/mL) 256 ±  423 263  ±  443 273  ±  447 0.22
URR  (%) 66.9  ±  7.0 67.3  ±  7.0 66.0  ±  7.8 0.20
hs-CRP  (mg/L) 6.02 ±  25 3.0 ±  4.2 7.1±  29.2 0.092
Hypertension 108  (68.8) 32  (69.6) 76  (68.5)  0.89a
Hypertriglyceridaemia 70 (44.6) 29  (63.0) 41  (36.9) 0.002a
Pre-existing  CVD  50  (31.8)  13  (28.3)  37  (33.3)  0.85a
Data are mean ± standard deviation or number (%). BMI: body mass index; CVD: cardiovascular disease; HDL-C: high-density lipoprotein
cholesterol; MS: metabolic syndrome; PTH: parathyroid hormone; SBP: systolic blood pressure; URR: urea reduction ratio; hs-CRP:
high-sensitivity C-reactive protein.
a 2 test.
b Data only available for 36 MS and 63 non-MS patients.
Table  2  Comparison  of  deaths  between  the  two  groups.
All  patients  (n  =  157)  MS  (n  =  46)  Non-MS  (n  =  111)  P
All-cause  mortality,  n  (%  of  total)  32  (20.4)  7  (15.2)  25  (22.5)  0.39a
Cause  of  death,  n  (%  of  deaths)
CVD  16  (50.0)  4  (57.1)  12  (48.0)  0.11a
Malignant  tumour  4  (12.5)  2  (28.6)  2  (8.0)  0.15a
Infection  6  (18.8)  0  6  (24.0)  0.15a
Malnutrition  4  (12.5)  0  4  (16.0)  0.26a
Hepatitis  C  cirrhosis  2  (6.3)  1  (14.3)  1  (4)  0.32a
Observed  survival  time  (months),  mean  ±  SD  30.7  ±  9.7  30.8  ±  7.3  29.8  ±  8.5  0.49
Total  survival  time  (months),  mean  ±  SD  74.0  ±  46.0  67.0  ±  43.0  78.0  ±  48.0  0.20
CVD: cardiovascular disease; MS: metabolic syndrome; SD: standard deviation.
a 2 test.
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Table  3  Comparison  of  selected  baseline  clinical  characteristics  between  surviving  patients  and  those  with  all-cause
mortality.
Survived  (n  =  125)  Died  (n  =  32)  P
Age  (years) 60  ±  12  67  ±  8  0.002
Men  69  (55.2)  18  (56.3)  1.0
Diabetic  nephropathy  22  (17.6)  8  (25.0)  0.47
Dialysis  vintage  (months)  43  ±  48  44  ±  38  0.99
SBP  predialysis  (mmHg) 143  ±  27 138  ±  35 0.38
BMI  (kg/m2)  23.7  ±  3.1 23.2  ±  5.7 0.55
Body  fat  (kg)a 27  ±  9 33  ±  16 0.25
Lean  body  mass  (kg)a 46.7  ±  8.3 41.4  ±  6.4 0.23
Muscle  mass  (kg)a 44.2  ±  8.0  39.1  ±  6.1  0.046
Visceral  fat  rating  (grade)a 11.0  ±  4.1  12.2  ±  5.6  0.35
Waist  circumference  (cm)  86  ±  7  87  ±  11  0.11
Malnutrition  37  (29.6)  28  (87.5)  <  0.001
Haemoglobin  (g/L) 113  ±  13 105  ±  20 0.07
Serum  albumin  (g/L) 40.5  ±  4.5 38.2  ±  3.5 0.003
Triglycerides  (mmol/L)  2.1  ±  1.4  1.9  ±  0.5  0.45
HDL-C  (mmol/L)  1.2  ±  0.5  1.5  ±  0.7  0.056
Total  cholesterol  (mmol/L)  4.3  ±  0.7  4.1  ±  0.8  0.20
MS  39  (31.2)  7  (21.9)  0.39
hs-CRP  (mg/L)  3.6  ±  10.8  15.9  ±  56.3  0.22
Pre-existing  CVD  34  (27.2)  16  (50.0)  0.01
Data are mean ± standard deviation or number (%). BMI: body mass index; CVD: cardiovascular disease; HDL-C: high-density lipoprotein
cholesterol; MS: metabolic syndrome; SBP: systolic blood pressure; hs-CRP: high-sensitivity C-reactive protein.
a Data only available for 11 patients who died and 88 who survived.
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of  haemodialysis  patients  have  been  found  to  have  MS  [8,9].Figure 1. Kaplan-Meier survival analysis of all-cause mortality in
patients with and without metabolic syndrome P = 0.30.
nephropathy  between  the  survival  and  mortality  groups
(Table  3).  The  percentage  of  patients  with  MS  was  higher
among  the  group  that  died  and  their  mean  hs-CRP  was  lower,
but  these  differences  were  not  signiﬁcant.Cox regression analysis of mortality risk
Cox  regression  analysis  was  performed  based  on  the  risk  fac-
tors  that  may  lead  to  CVD  or  all-cause  mortality.  Based  on
O
e
Dhe  Table  3  results,  the  analysis  was  focused  on  age,  serum
lbumin  and  pre-existing  CVD.  The  effects  of  MS  were  also
nalysed.  None  of  these  factors  were  found  to  affect  CVD-
elated  mortality,  but  there  were  signiﬁcant  differences  in
ll-cause  mortality.  The  independent  risk  factors  for  all-
ause  mortality  were:  being  more  than  or  equal  to  66  years
ld,  having  serum  albumin  less  than  37  g/L  and  having  pre-
xisting  CVD  (Table  4)  but  MS  was  not  the  independent
ortality  risk  factor.
iscussion
n  this  prospective,  observational  cohort  study  we  collected
ata  related  to  age,  sex  and  BMI,  as  well  as  other  basic  infor-
ation,  and  found  that  our  data  were  distributed  similarly  to
ther  studies  of  Asian  patients  [15]. However,  patients  with
S  accounted  for  30%  of  the  cohort,  which  is  lower  than
as  been  found  in  haemodialysis  patients  in  other  devel-
ped  regions  (44%  in  Asian  American  patients  [16]  and  46%
n  Taiwanese  patients  [17]). This  may  be  due  to  the  use  of
ifferent  deﬁnitions  of  MS.
In the  general  population,  MS  is  well  known  to  be  asso-
iated  with  a  higher  risk  of  cardiovascular  events  [1,18,19].
any  studies,  and  the  data  presented  here,  suggest  that  CVD
vents  account  for  approximately  50%  of  the  mortality  of
aemodialysis  patients  [2,3]. Meanwhile,  a  high  proportionverall,  the  relationship  between  prognosis  and  the  pres-
nce  of  MS  in  haemodialysis  patients  has  not  been  resolved.
ata  from  Taiwan  have  shown  that  haemodialysis  patients
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Table  4  Cox  regression  analysis  of  the  risk  factors  for  all-cause  mortality.
Risk  factors  B  SE  Wald  P  Exp(B)  95%  CI  of  Exp(B)
Age  (<  vs.  ≥  66  years) —0.979  0.502  3.957  0.045  0.441  0.148—1.057
Serum  albumin  (≥  vs.  <  37  g/L)  —1.535  0.755  4.183  0.032  0.329  0.049—0.945
Pre-existing  CVD  (no  vs.  yes)  —1.111  0.490  5.120  0.024  0.279  0.126—0.862
B: regression coefﬁcient; CI: conﬁdence interval of Exp(B); Exp(B): Hazard Ratio; SE: standard error of regression coefﬁcient.
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Rith  MS  (as  deﬁned  by  the  NCEP/ATP  III  Asian  criteria  [4])  had
igher  hospitalization  rates  than  those  without  MS,  although
here  were  no  signiﬁcant  differences  in  CVD  or  all-cause
ortality  [17].
In the  present  study,  we  used  the  IDF  criteria  for  MS  [5].
hese  criteria  have  been  revised  to  deﬁne  central  obesity
ased  on  the  core  content  to  better  predict  CVD  risk.  Accord-
ng  to  the  IDF  criteria,  patients  who  have  central  obesity  and
wo  other  variables  are  deﬁned  as  having  MS.  Currently,  it  is
till  inconclusive  whether  the  IDF  deﬁnition  of  MS  can  suc-
essfully  predict  high  CVD  risk  in  long-term  haemodialysis
atients.
In  this  study,  we  classiﬁed  the  patients  into  groups  based
n  the  IDF  criteria  and  performed  a  prospective  cohort  study
ocusing  on  the  relationship  between  MS  and  the  risk  of
eath  in  haemodialysis  patients.  Based  on  our  results,  we
onclude  that  MS  does  not  increase  the  risk  of  CVD  or  all-
ause  mortality  in  haemodialysis  patients  and  is  consistent
ith  other  authors’  reports  [17]. Furthermore,  CVD  and  all-
ause  mortality  rates  were  actually  numerically  (though  not
igniﬁcantly)  lower  among  MS  patients  than  among  those
ithout  MS  (CVD:  8.7%  vs.  10.8%;  all-cause:  15.2%  vs.  22.5%).
hether  this  observation  could  have  been  signiﬁcant  with  a
arger  sample  size  is  not  clear.  Conversely,  mean  total  sur-
ival  time  was  shorter  among  patients  with  MS  (67  vs.  78
onths)  although,  again,  this  was  not  signiﬁcant.  This  means
hat,  using  the  IDF  deﬁnition  of  MS,  we  did  not  ﬁnd  a  ﬁrm  link
etween  MS  and  CVD  or  all-cause  mortality  in  haemodialysis
atients.
There  may  be  certain  factors  that  could  weaken  the
ffects  of  MS  on  CVD  and  all-cause  mortality  among  long-
erm  haemodialysis  patients.  Firstly,  some  patients  with
ype  2  diabetes  mellitus  and  MS  were  excluded  from  our
tudy  because  they  had  a  smaller  waist  circumference  than
hat  speciﬁed  by  the  IDF  [5].  Secondly,  our  follow-up  time
as  relatively  short  and  our  sample  size  from  only  a  single
entre  was  relatively  small.  Moreover,  our  result  that  pre-
xisting  CVD  was  strongly  associated  with  all-cause  mortality
lso  means  that  pre-existing  CVD  affected  patients’  survival
ver  the  shorter  time  whereas  metabolic  syndrome  might
ffect  patients’  survival  over  a  longer  time.  These  reasons
ay  have  masked  any  effect  of  MS  on  CVD  and  all-cause
ortality  in  haemodialysis  patients.
Conversely,  there  are  some  factors  that  may  predispose
aemodialysis  patients  to  CVD  and  all-cause  mortality,  other
han  MS,  most  obviously,  malnutrition.  There  were  more
atients  with  malnutrition  (B,  assessed  by  SGA)  in  the  group
ithout  MS;  and  more  patients  with  malnutrition  in  the  mor-
ality  group  than  in  the  survival  group.  The  Cox  regression
nalysis  also  showed  that  serum  albumin  less  than  37  g/L
as  an  independent  risk  factor  for  all-cause  mortality  inhese  haemodialysis  patients.  It  should  be  noted  that  the
en  patients  who  died  of  severe  lung  infection  or  severe
alnutrition.  To  some  extent,  nutrition  in  patients  with  MS
as  found  to  be  relatively  better  than  in  patients  without
S.  Previous  studies  have  found  that  comorbid  conditions  in
aemodialysis  patients,  such  as  hyperlipidaemia,  hyperten-
ion  and  obesity,  are  often  associated  with  a  relatively  good
rognosis  [10—12]. It  is  possible  that  these  patients  there-
ore  have  relatively  good  nutritional  status.  Stolic  et  al.  have
ecently  reported  that  haemodialysis  patients  with  malnutri-
ion  had  a  lower  rate  of  survival  than  those  with  MS,  and  that
alnutrition  increased  the  risk  of  mortality  in  haemodialysis
atients  compared  with  MS  [20]. All  of  these  factors  suggest
hat  the  potential  role  of  malnutrition  in  the  mortality  of
aemodialysis  patients  should  not  be  ignored.
onclusions
n  this  prospective  cohort  study,  30%  of  haemodialysis
atients  had  MS,  deﬁned  according  to  the  IDF  criteria  [5].
S  was  associated  with  better  nutritional  status,  while  it
as  not  associated  with  CVD  or  all-cause  mortality  in  these
aemodialysis  patients.  The  independent  risk  factors  for  all-
ause  mortality  were:  pre-existing  CVD,  low  albumin  levels
indicating  malnutrition)  and  older  age  (older  than  66  years).
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